RetinalGenix Technologies Inc. (RTGN) Research

RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.

Market snapshot

Symbol
RTGN
Price
$4.00
Day change
0.00%
Market cap
$75.4M
P/E ratio
-30.85x
52-week range
3.2-5.02
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Biocartis Group N.V. (BIOGF)
  • Carmat S.A. (CKMTF)
  • Elegance Optical International Holdings Limited (EEOIF)
  • Goodness Growth Holdings, Inc. (GDNSF)
  • Healthcare Integrated Technologies, Inc. (HITC)
  • INNOCAN PHARMA Corp (INNPF)
  • Karolinska Development AB (publ) (KDEVF)
  • Kiaro Holdings Corp. (KIARF)

Recent insider activity

  • Conley Richard K — A-Award (5000 shares) on 2015-04-30
  • Akao Akihisa — A-Award (5000 shares) on 2015-04-30
  • Oculus Innovative Sciences, Inc. — S-Sale (350000 shares) on 2015-03-23
  • Akao Akihisa — trade (0 shares) on 2015-02-27
  • Conley Richard K — A-Award (58000 shares) on 2014-05-11

Open RetinalGenix Technologies Inc. (RTGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.